Arturo M. Lichauco
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Arturo M. Lichauco has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
A. Serrero
Xeltis B.V., Eindhoven, Netherlands
1 shared publication- Anthal I. P. M. Smits
Department of Biomedical Engineering, Eindhoven University of Technology
1 shared publication - Bente J. de Kort
Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, The Netherlands
1 shared publication C.V.C. Bouten
Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, Netherlands; Institute for Complex Molecular Systems (ICMS), Eindhoven University of Technology, Eindhoven, Netherlands
1 shared publication- Carlijn V. C. Bouten
Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, The Netherlands
1 shared publication - Dan Wu
Chongqing Univ. of Posts and Telecommunications (China)
1 shared publication
Latest Publications
- Open Access
- 26 March 2024
- Published by Wiley in Advanced Healthcare Materials
- Vol. 13 (17) , e2303888
Off‐the‐Shelf Synthetic Biodegradable Grafts Transform In Situ into a Living Arteriovenous Fistula in a Large Animal Model
Current vascular access options require frequent interventions. In situ tissue engineering (TE) may overcome these limitations by combining the initial success of synthetic grafts with long‐term advantages of autologous vessels by using biodegradable grafts that transform into autologous vascular tissue at the site of implantation. Scaffolds (6 mm‐Ø) made of supramolecular polycarbonate‐bisurea (PC‐BU), with a polycaprolactone (PCL) anti‐kinking‐coil, are implanted between the carotid artery and jugular vein in goats. A subset is bio‐functionalized using bisurea‐modified‐Stromal cell‐derived factor‐1α (SDF1α) derived peptides and ePTFE grafts as controls. Grafts are explanted after 1 and 3 months, and evaluated for material degradation, tissue formation, compliance, and patency. At 3 months, the scaffold is resorbed and replaced by vascular neo‐tissue, including elastin, contractile markers, and endothelial lining. No dilations, ruptures, or aneurysms are observed and grafts are successfully cannulated at termination. SDF‐1α‐peptide‐biofunctionalization does not influence outcomes. Patency is lower in TE grafts (50%) compared to controls (100% patency), predominantly caused by intimal hyperplasia. Rapid remodeling of a synthetic, biodegradable vascular scaffold into a living, compliant arteriovenous fistula is demonstrated in a large animal model. Despite lower patency compared to ePTFE, transformation into autologous and compliant living tissue with self‐healing capacity may have long‐term advantages.
- 26 March 2024
- Published by Wiley in Advanced Healthcare Materials
- Vol. 13 (17) , e2303888
Open AccessOff‐the‐Shelf Synthetic Biodegradable Grafts Transform In Situ into a Living Arteriovenous Fistula in a Large Animal Model
Current vascular access options require frequent interventions. In situ tissue engineering (TE) may overcome these limitations by combining the initial success of synthetic grafts with long‐term advantages of autologous vessels by using biodegradable grafts that transform into autologous vascular tissue at the site of implantation. Scaffolds (6 mm‐Ø) made of supramolecular polycarbonate‐bisurea (PC‐BU), with a polycaprolactone (PCL) anti‐kinking‐coil, are implanted between the carotid artery and jugular vein in goats. A subset is bio‐functionalized using bisurea‐modified‐Stromal cell‐derived factor‐1α (SDF1α) derived peptides and ePTFE grafts as controls. Grafts are explanted after 1 and 3 months, and evaluated for material degradation, tissue formation, compliance, and patency. At 3 months, the scaffold is resorbed and replaced by vascular neo‐tissue, including elastin, contractile markers, and endothelial lining. No dilations, ruptures, or aneurysms are observed and grafts are successfully cannulated at termination. SDF‐1α‐peptide‐biofunctionalization does not influence outcomes. Patency is lower in TE grafts (50%) compared to controls (100% patency), predominantly caused by intimal hyperplasia. Rapid remodeling of a synthetic, biodegradable vascular scaffold into a living, compliant arteriovenous fistula is demonstrated in a large animal model. Despite lower patency compared to ePTFE, transformation into autologous and compliant living tissue with self‐healing capacity may have long‐term advantages.
- Open Access
- 1 November 2021
- Published by Elsevier in Acta Biomaterialia
- Vol. 135, 243-259
Inflammatory and regenerative processes in bioresorbable synthetic pulmonary valves up to two years in sheep–Spatiotemporal insights augmented by Raman microspectroscopy
- 1 November 2021
- Published by Elsevier in Acta Biomaterialia
- Vol. 135, 243-259
Open AccessInflammatory and regenerative processes in bioresorbable synthetic pulmonary valves up to two years in sheep–Spatiotemporal insights augmented by Raman microspectroscopy